NCT05622240 is a EARLY_PHASE1 clinical trial of 99mTc-MIRC213 in Breast Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05622240?

NCT05622240 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05622240?

Interventions in NCT05622240: 99mTc-MIRC213.

What condition does NCT05622240 study?

NCT05622240 studies Breast Cancer.

Is NCT05622240 still recruiting?

NCT05622240 is currently status unknown. Last updated 21 November 2022.

Last reviewed 2022-11-21 · How we verify

NCT05622240

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer

Status unknown EARLY_PHASE1 Last updated 21 November 2022

What this trial tests

EARLY_PHASE1 trial testing 99mTc-MIRC213 in Breast Cancer in 30 participants. Status unknown.

Timeline

7 September 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	7 September 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

99mTc-MIRC213 — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

Under 85, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.
Zeven K, Lauwers Y, De Mey L, Debacker JM, et al · · 2024 · cited 8× · PMID 39281708 · DOI 10.1093/immadv/ltae006
Current Approaches of Nuclear Molecular Imaging in Breast Cancer.
Schäfer L, Altunay B, Heesch A, van Nijnatten T, et al · · 2025 · PMID 40647404 · DOI 10.3390/cancers17132105

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05622240 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 21 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05622240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing